2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
L

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New SoC as First-line Therapy in Patients With MSI-H mCRC?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Louise Connell
By 2020 ASCO Virtual Direct™ Highlights FEATURING Louise Connell
493 views
July 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn
GI
11:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Locoregional CRC: 3 vs. 6 Months of Adjuvant Oxa…

Feat. L. Connell
09:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Should Pembrolizumab Be The New So…

Feat. L. Connell
14:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced CRC: Is Recently FDA Approved Encorafen…

Feat. L. Connell
12:38
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Pancreatic Cancer Update: Does Gemcitabine + Nab-paclitaxe…

Feat. C. Lima
08:03
2020 ASCO Virtual Direct™ Highlights

2020 ASCO HCC Update: Is Tremelimumab + Durvalumab Effective, Tolera…

Feat. C. Lima
11:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Gastric & Esophageal: Does the Addition of P…

Feat. C. Lima